Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu7 Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962)
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Herein, we report the discovery of a new, orally bioavailable and CNS-penetrant metabotropic
glutamate receptor 7 (mGlu 7 ) negative allosteric modulator (NAM) that achieves exposure
in cerebral spinal fluid (CSF) 2.5× above the in vitro IC 50 at minimum effective
doses (MEDs) of 3 mg/kg in preclinical anxiety models.